IBDEI0IY ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,8528,1,3,0)
;;=3^Carcinoma in Situ of Endocervix
;;^UTILITY(U,$J,358.3,8528,1,4,0)
;;=4^D06.0
;;^UTILITY(U,$J,358.3,8528,2)
;;=^5001938
;;^UTILITY(U,$J,358.3,8529,0)
;;=D06.1^^39^401^48
;;^UTILITY(U,$J,358.3,8529,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8529,1,3,0)
;;=3^Carcinoma in Situ of Exocervix
;;^UTILITY(U,$J,358.3,8529,1,4,0)
;;=4^D06.1
;;^UTILITY(U,$J,358.3,8529,2)
;;=^5001939
;;^UTILITY(U,$J,358.3,8530,0)
;;=D06.7^^39^401^46
;;^UTILITY(U,$J,358.3,8530,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8530,1,3,0)
;;=3^Carcinoma in Situ of Cervix,Other Parts
;;^UTILITY(U,$J,358.3,8530,1,4,0)
;;=4^D06.7
;;^UTILITY(U,$J,358.3,8530,2)
;;=^5001940
;;^UTILITY(U,$J,358.3,8531,0)
;;=D04.9^^39^401^49
;;^UTILITY(U,$J,358.3,8531,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8531,1,3,0)
;;=3^Carcinoma in Situ of Skin
;;^UTILITY(U,$J,358.3,8531,1,4,0)
;;=4^D04.9
;;^UTILITY(U,$J,358.3,8531,2)
;;=^5001925
;;^UTILITY(U,$J,358.3,8532,0)
;;=C91.11^^39^401^52
;;^UTILITY(U,$J,358.3,8532,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8532,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
;;^UTILITY(U,$J,358.3,8532,1,4,0)
;;=4^C91.11
;;^UTILITY(U,$J,358.3,8532,2)
;;=^5001766
;;^UTILITY(U,$J,358.3,8533,0)
;;=C91.10^^39^401^53
;;^UTILITY(U,$J,358.3,8533,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8533,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
;;^UTILITY(U,$J,358.3,8533,1,4,0)
;;=4^C91.10
;;^UTILITY(U,$J,358.3,8533,2)
;;=^5001765
;;^UTILITY(U,$J,358.3,8534,0)
;;=C92.11^^39^401^54
;;^UTILITY(U,$J,358.3,8534,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8534,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
;;^UTILITY(U,$J,358.3,8534,1,4,0)
;;=4^C92.11
;;^UTILITY(U,$J,358.3,8534,2)
;;=^5001793
;;^UTILITY(U,$J,358.3,8535,0)
;;=C92.10^^39^401^55
;;^UTILITY(U,$J,358.3,8535,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8535,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
;;^UTILITY(U,$J,358.3,8535,1,4,0)
;;=4^C92.10
;;^UTILITY(U,$J,358.3,8535,2)
;;=^5001792
;;^UTILITY(U,$J,358.3,8536,0)
;;=D47.1^^39^401^56
;;^UTILITY(U,$J,358.3,8536,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8536,1,3,0)
;;=3^Chronic Myeloproliferative Disease
;;^UTILITY(U,$J,358.3,8536,1,4,0)
;;=4^D47.1
;;^UTILITY(U,$J,358.3,8536,2)
;;=^5002256
;;^UTILITY(U,$J,358.3,8537,0)
;;=C82.69^^39^401^57
;;^UTILITY(U,$J,358.3,8537,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8537,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8537,1,4,0)
;;=4^C82.69
;;^UTILITY(U,$J,358.3,8537,2)
;;=^5001530
;;^UTILITY(U,$J,358.3,8538,0)
;;=C82.60^^39^401^58
;;^UTILITY(U,$J,358.3,8538,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8538,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,8538,1,4,0)
;;=4^C82.60
;;^UTILITY(U,$J,358.3,8538,2)
;;=^5001521
;;^UTILITY(U,$J,358.3,8539,0)
;;=D56.2^^39^401^59
;;^UTILITY(U,$J,358.3,8539,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8539,1,3,0)
;;=3^Delta-Beta Thalassemia
;;^UTILITY(U,$J,358.3,8539,1,4,0)
;;=4^D56.2
;;^UTILITY(U,$J,358.3,8539,2)
;;=^340496
;;^UTILITY(U,$J,358.3,8540,0)
;;=D75.9^^39^401^60
;;^UTILITY(U,$J,358.3,8540,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8540,1,3,0)
;;=3^Disease of Blood/Blood-Forming Organs,Unspec
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0IY 3825 printed Sep 23, 2025@19:25:35 Page 2
IBDEI0IY ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,8528,1,3,0)
+2 ;;=3^Carcinoma in Situ of Endocervix
+3 ;;^UTILITY(U,$J,358.3,8528,1,4,0)
+4 ;;=4^D06.0
+5 ;;^UTILITY(U,$J,358.3,8528,2)
+6 ;;=^5001938
+7 ;;^UTILITY(U,$J,358.3,8529,0)
+8 ;;=D06.1^^39^401^48
+9 ;;^UTILITY(U,$J,358.3,8529,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,8529,1,3,0)
+12 ;;=3^Carcinoma in Situ of Exocervix
+13 ;;^UTILITY(U,$J,358.3,8529,1,4,0)
+14 ;;=4^D06.1
+15 ;;^UTILITY(U,$J,358.3,8529,2)
+16 ;;=^5001939
+17 ;;^UTILITY(U,$J,358.3,8530,0)
+18 ;;=D06.7^^39^401^46
+19 ;;^UTILITY(U,$J,358.3,8530,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,8530,1,3,0)
+22 ;;=3^Carcinoma in Situ of Cervix,Other Parts
+23 ;;^UTILITY(U,$J,358.3,8530,1,4,0)
+24 ;;=4^D06.7
+25 ;;^UTILITY(U,$J,358.3,8530,2)
+26 ;;=^5001940
+27 ;;^UTILITY(U,$J,358.3,8531,0)
+28 ;;=D04.9^^39^401^49
+29 ;;^UTILITY(U,$J,358.3,8531,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,8531,1,3,0)
+32 ;;=3^Carcinoma in Situ of Skin
+33 ;;^UTILITY(U,$J,358.3,8531,1,4,0)
+34 ;;=4^D04.9
+35 ;;^UTILITY(U,$J,358.3,8531,2)
+36 ;;=^5001925
+37 ;;^UTILITY(U,$J,358.3,8532,0)
+38 ;;=C91.11^^39^401^52
+39 ;;^UTILITY(U,$J,358.3,8532,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,8532,1,3,0)
+42 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
+43 ;;^UTILITY(U,$J,358.3,8532,1,4,0)
+44 ;;=4^C91.11
+45 ;;^UTILITY(U,$J,358.3,8532,2)
+46 ;;=^5001766
+47 ;;^UTILITY(U,$J,358.3,8533,0)
+48 ;;=C91.10^^39^401^53
+49 ;;^UTILITY(U,$J,358.3,8533,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,8533,1,3,0)
+52 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
+53 ;;^UTILITY(U,$J,358.3,8533,1,4,0)
+54 ;;=4^C91.10
+55 ;;^UTILITY(U,$J,358.3,8533,2)
+56 ;;=^5001765
+57 ;;^UTILITY(U,$J,358.3,8534,0)
+58 ;;=C92.11^^39^401^54
+59 ;;^UTILITY(U,$J,358.3,8534,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,8534,1,3,0)
+62 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
+63 ;;^UTILITY(U,$J,358.3,8534,1,4,0)
+64 ;;=4^C92.11
+65 ;;^UTILITY(U,$J,358.3,8534,2)
+66 ;;=^5001793
+67 ;;^UTILITY(U,$J,358.3,8535,0)
+68 ;;=C92.10^^39^401^55
+69 ;;^UTILITY(U,$J,358.3,8535,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,8535,1,3,0)
+72 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
+73 ;;^UTILITY(U,$J,358.3,8535,1,4,0)
+74 ;;=4^C92.10
+75 ;;^UTILITY(U,$J,358.3,8535,2)
+76 ;;=^5001792
+77 ;;^UTILITY(U,$J,358.3,8536,0)
+78 ;;=D47.1^^39^401^56
+79 ;;^UTILITY(U,$J,358.3,8536,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,8536,1,3,0)
+82 ;;=3^Chronic Myeloproliferative Disease
+83 ;;^UTILITY(U,$J,358.3,8536,1,4,0)
+84 ;;=4^D47.1
+85 ;;^UTILITY(U,$J,358.3,8536,2)
+86 ;;=^5002256
+87 ;;^UTILITY(U,$J,358.3,8537,0)
+88 ;;=C82.69^^39^401^57
+89 ;;^UTILITY(U,$J,358.3,8537,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,8537,1,3,0)
+92 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
+93 ;;^UTILITY(U,$J,358.3,8537,1,4,0)
+94 ;;=4^C82.69
+95 ;;^UTILITY(U,$J,358.3,8537,2)
+96 ;;=^5001530
+97 ;;^UTILITY(U,$J,358.3,8538,0)
+98 ;;=C82.60^^39^401^58
+99 ;;^UTILITY(U,$J,358.3,8538,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,8538,1,3,0)
+102 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
+103 ;;^UTILITY(U,$J,358.3,8538,1,4,0)
+104 ;;=4^C82.60
+105 ;;^UTILITY(U,$J,358.3,8538,2)
+106 ;;=^5001521
+107 ;;^UTILITY(U,$J,358.3,8539,0)
+108 ;;=D56.2^^39^401^59
+109 ;;^UTILITY(U,$J,358.3,8539,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,8539,1,3,0)
+112 ;;=3^Delta-Beta Thalassemia
+113 ;;^UTILITY(U,$J,358.3,8539,1,4,0)
+114 ;;=4^D56.2
+115 ;;^UTILITY(U,$J,358.3,8539,2)
+116 ;;=^340496
+117 ;;^UTILITY(U,$J,358.3,8540,0)
+118 ;;=D75.9^^39^401^60
+119 ;;^UTILITY(U,$J,358.3,8540,1,0)
+120 ;;=^358.31IA^4^2
+121 ;;^UTILITY(U,$J,358.3,8540,1,3,0)
+122 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
